Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 78, Issue 4, Pages 748-762
Publisher
Wiley
Online
2014-03-25
DOI
10.1111/bcp.12387
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of Hypertension in Cancer Patients Treated with Aflibercept: A Systematic Review and Meta-Analysis
- (2014) Wei-Xiang Qi et al. CLINICAL DRUG INVESTIGATION
- Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
- (2013) W.-X. Qi et al. ANNALS OF ONCOLOGY
- Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer
- (2013) Giuseppe Curigliano et al. BREAST
- A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
- (2013) Stephen R. D. Johnston et al. BREAST CANCER RESEARCH AND TREATMENT
- Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy
- (2013) Roberto Iacovelli et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials
- (2013) Roberto Iacovelli et al. CANCER TREATMENT REVIEWS
- Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
- (2013) John D. Hainsworth et al. Clinical Genitourinary Cancer
- Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis
- (2013) Wei-Xiang Qi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials
- (2013) Matteo Santoni et al. INTERNATIONAL JOURNAL OF CANCER
- Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study
- (2013) David M. Hyams et al. INVESTIGATIONAL NEW DRUGS
- Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial
- (2013) Craig Reynolds et al. INVESTIGATIONAL NEW DRUGS
- Cediranib for Metastatic Alveolar Soft Part Sarcoma
- (2013) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
- (2012) Massimo Cristofanilli et al. BREAST CANCER RESEARCH AND TREATMENT
- Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
- (2012) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
- (2012) Wei-Xiang Qi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
- (2012) Shanthi Sivendran et al. CANCER TREATMENT REVIEWS
- Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised phase II study
- (2012) Peter Mulders et al. EUROPEAN JOURNAL OF CANCER
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
- (2012) Jonas Bergh et al. JOURNAL OF CLINICAL ONCOLOGY
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
- (2012) Fabio A.B. Schutz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib
- (2011) Christopher J. Richards et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- (2011) Samuel A. Wells et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
- (2010) Carlos H. Barrios et al. BREAST CANCER RESEARCH AND TREATMENT
- Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma
- (2010) Ghassan K. Abou-Alfa et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma
- (2010) Y. Tomita et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Clinical Efficacy and Safety of Sunitinib After Imatinib Failure in Japanese Patients with Gastrointestinal Stromal Tumor
- (2010) K. Matsumoto et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
- (2010) Vishnu Chintalgattu et al. JOURNAL OF CLINICAL INVESTIGATION
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) Sanjaykumar Hapani et al. ONCOLOGY
- Phase II study of sunitinib in men with advanced prostate cancer
- (2009) M. Dror Michaelson et al. ANNALS OF ONCOLOGY
- Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
- (2009) Loukas F Kontovinis et al. BMC CANCER
- Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma
- (2009) Hendrieke Hoftijzer et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study
- (2009) Martee L. Hensley et al. GYNECOLOGIC ONCOLOGY
- A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184
- (2009) Helen J. Mackay et al. GYNECOLOGIC ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma
- (2009) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
- (2009) Robert G. Maki et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
- (2009) Youjin Je et al. LANCET ONCOLOGY
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation